Hormonal Aspects of Breast Cancer Web-Based Lecture Series Archive

Please register below for a
previously recorded HABC Web-Based Lecture Series
 
Please be aware that we will use your personally identifiable information to contact you about your participation in the program. This information is governed by AstraZeneca’s Privacy Policy.

AstraZeneca respects your personal information. The information you provide may be used to send you materials and to develop products, services, and programs. AstraZeneca, or third parties working on our behalf, will not sell or rent your personal information. Please visit www.azprivacystatement.com to review our Privacy Statement.

By submitting this information, you agree to these conditions.

 Registration for Previously Recorded Program
Early Breast Cancer Topics:
Speaker Topic Select
Michael Naughton, MD ARIMIDEX® (anastrozole) in Early Breast Cancer: 100-Month Follow-up of ATAC
Michael Naughton, MD Understanding Clinical Trial Design and Results in the Context of Early Breast Cancer
John Glaspy, MD Strength of Evidence: ARIMIDEX® (anastrozole) in Early Breast Cancer
Christy Russell, MD Challenging Cases in Early Breast Cancer: Perimenopausal Woman Diagnosed With Early Breast Cancer
Christy Russell, MD Challenging Cases in Early Breast Cancer: Postmenopausal Woman With Early Breast Cancer and Potential Comorbidities
Christy Russell, MD The Facts About Cancer Survivorship: What You Need To Know
Christy Russell, MD Survivorship and Side Effects in Early Breast Cancer
Patricia DeFusco, MD The Facts About Cancer Survivorship: What You Need To Know
Yvonne Bossert, RN, OCN Understanding Adherence To Oral Medication: Early Breast Cancer
Mark Pegram, MD Interpreting Clinical Trial Results for Adjuvant Hormonal Therapy of Breast Cancer
   
Metastatic Breast Cancer Topics:
Speaker Topic Select
Hope Rugo, MD FASLODEX® (fulvestrant) Injection: Directly Targeting the Estrogen Receptor Pathway in Metastatic Breast Cancer
William Gradishar, MD Challenging Cases in Metastatic Breast Cancer: Patient With a History of Breast Cancer Who Did Not Receive Adjuvant Hormonal Therapy
William Gradishar, MD Challenging Cases in Metastatic Breast Cancer: Patient with a History of Breast Cancer Presents With Hip Pain

Archive Video Preview
   
* First/Last Name, Degree :   ,
* Specialty:  
Affiliation:  
* Country:  
* Address 1:  
Address 2:  
* City, State and Zip Code:   ,  
* Phone Number:  
Fax Number:  
Cell Phone Number:  
* E-mail Address:  
* Verify E-mail Address:   
Yes, I would like to enroll to receive e-mail invitations for upcoming events in the Hormonal Aspects of Breast Cancer series
Yes, I would like to receive information in the future about breast cancer and related AstraZeneca products and services
   

* denotes required field 



Comments to AstraZeneca: AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism. If you have any comments which could improve the delivery of our promotional educational programs please contact AstraZeneca at: 1-800-236-9933
Important Information About ARIMIDEX® (anastrozole) Tablets

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

ARIMIDEX is only for postmenopausal women. ARIMIDEX can cause fetal harm when administered to a pregnant woman. Before starting treatment with ARIMIDEX, pregnancy must be excluded (see CONTRAINDICATIONS section of full Prescribing Information).

In women with preexisting ischemic heart disease 465/6186 (7.5%), an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX (17%) vs tamoxifen (10%). In this patient population, angina pectoris was reported in 25/216 (11.6%) vs 13/249 (5.2%) and myocardial infarction was reported in 2/216 (0.9%) vs 8/249 (3.2%) patients receiving ARIMIDEX and tamoxifen, respectively.

Compared to baseline, ARIMIDEX showed a mean decrease in both lumbar spine and total hip bone mineral density. Tamoxifen showed a mean increase in these measurements. Nine percent of patients receiving ARIMIDEX had an elevated serum cholesterol vs 3.5% of patients receiving tamoxifen.

Common side effects seen with ARIMIDEX vs tamoxifen in the early breast cancer trial after 5 years of treatment include hot flashes (36% vs 41%), joint disorders (including arthritis, arthrosis, arthralgia) (36% vs 29%), asthenia (19% vs 18%), mood disturbances (19% vs 18%), pain (17% vs 16%), pharyngitis (14% vs 14%), nausea and vomiting (13% vs 12%), rash (11% vs 13%), depression (13% vs 12%), hypertension (13% vs 11%), osteoporosis (11% vs 7%), peripheral edema (10% vs 11%), lymphedema (10% vs 11%), back pain (10% vs 10%), insomnia (10% vs 9%), and headache (10% vs 8%). Fractures, including fractures of the spine, hip, and wrist, occurred more often with ARIMIDEX vs tamoxifen (10% vs 7%).

In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking ARIMIDEX included hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis, and peripheral edema. Joint pain/stiffness has been reported in association with the use of ARIMIDEX.

Clinical and pharmacokinetic results suggest that tamoxifen should not be administered with ARIMIDEX. Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

View ARIMIDEX full Prescribing Information

Important Information About FASLODEX® (fulvestrant) Injection

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Important Safety Information About FASLODEX

FASLODEX is only for postmenopausal women. FASLODEX can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while receiving FASLODEX. (See CONTRAINDICATIONS and WARNINGS sections of full Prescribing Information.)

Because FASLODEX is administered intramuscularly, it should not be used in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants.

In clinical trials, the most commonly reported adverse events seen with FASLODEX, regardless of the investigator's assessment of causality, were gastrointestinal symptoms (nausea 26.0%, vomiting 13.0%, constipation 12.5%, diarrhea 12.3%, abdominal pain 11.8%), headache (15.4%), back pain (14.4%), hot flushes (17.7%), and pharyngitis (16.1%). Injection site reactions with mild, transient pain and inflammation were reported in 7% of patients (1% of treatments) given single 5 mL injection and 27% of patients (4.6% of treatments) given 2 x 2.5 mL injections of FASLODEX.

View FASLODEX full Prescribing Information
 
ARIMIDEX and FASLODEX are registered trademarks of the AstraZeneca group of companies.
© 2010 AstraZeneca Pharmaceuticals LP. All rights reserved. 302793 6/10